ROR-1 Targeted CAR-T Cells for Hematological Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies for cancer, such as those targeting CD19, face challenges in specificity and efficacy due to varying structures and production methods, and there is a need for effective treatments for cancers expressing ROR-1 antigen.
Innovation Solution
Development of chimeric antigen receptors (CARs) specifically targeting ROR-1, comprising an antigen binding region, spacer domain, transmembrane domain, and intracellular signaling domains, optimized for improved function and expressed in T lymphocytes for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple different CAR structures and production methods are used to treat various cancers, then the versatility and coverage of cancer treatment is improved, but the complexity of pharmacology and manufacturing increases
Solution Approach 1:
The patent develops CAR structures with universal design elements that can target multiple cancer-associated antigens including ROR-1, CD19, and other markers. The standardized modular CAR architecture allows a single platform to be adapted for treating diverse cancers through antigen-specific variable regions, thereby improving treatment versatility while maintaining consistent manufacturing and pharmacological principles across different cancer types.
2Reliability
If CAR-T cells are optimized with specific spacer lengths and signaling domains to improve function, then the therapeutic efficacy is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent systematically evaluates and optimizes specific parameters of the CAR structure including spacer domain lengths (comparing 15aa versus 24aa spacers) and intracellular signaling domain configurations. Through controlled parameter variations in preclinical studies, the patent identifies optimal configurations that maximize therapeutic efficacy while establishing standardized manufacturing specifications that balance precision requirements with production feasibility.
3Measurement precision
If autologous CAR-T products are customized for each patient to improve specificity, then the treatment precision is improved, but the production time and complexity increase
Solution Approach 1:
The patent employs pre-validated CAR designs and standardized manufacturing protocols that have been optimized in advance for targeting specific cancer antigens. By preparing standardized CAR constructs and manufacturing processes beforehand, the system reduces the time required for personalized CAR-T production while maintaining high antigen targeting precision through pre-characterized variable regions and optimized signaling domains.
Data Source
AI summary
Provided herein is a chimeric antigen receptor (CAR) and CAR-expressing immune cells that target human RORI expressed aberrantly on a tumor cancers. Described herein are chimeric antigen receptors that target human ROR-1, cell compositions expressing the chimeric antigen receptors, and methods and uses of the chimeric antigen receptors and/or the cell compositions. The chimeric antigen receptors described herein can be expressed by the T lymphocytes isolated from an individual afflicted with cancer and re-administered to the individual.